V-8400 Vincristine, Sulfate Salt, >99%

Synonyms : [LCR sulfate] [Leurocristine sulfate] [Lilly 37231] [22-Oxovincaleukoblastine sulfate] [VCR sulfate] [Vincristine hydrogen sulfate]

Related Terms : [Kyocristine] [Marqibo] [Novopharm] [Oncovin] [Onkovin] [Vincasar PFS] [Vincrex] [Vincrisul]

  • Size
  • US $
  • £
  • ¥
  • 10 mg
  • 38
  • 33
  • 29
  • 4,200
  • Add to Cart
  • Out of stock
  • 25 mg
  • 71
  • 63
  • 55
  • 7,900
  • Add to Cart
  • Out of stock
  • 50 mg
  • 114
  • 101
  • 89
  • 12,700
  • Add to Cart
  • Out of stock
  • 100 mg
  • 182
  • 162
  • 142
  • 20,300
  • Add to Cart
  • Out of stock
  • 200 mg
  • 325
  • 290
  • 253
  • 36,200
  • Add to Cart
  • Out of stock
  • 500 mg
  • 515
  • 459
  • 402
  • 57,300
  • Add to Cart
  • Out of stock
  • 1 g
  • 922
  • 823
  • 720
  • 102,600
  • Add to Cart
  • Out of stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 923.04
  • C46H56N4O10•H2SO4
  • [2068-78-2]
  • M.I. 14: 9986

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 60 mg/mL; very poorly soluble in ethanol; soluble in water at 25 mg/mL with warming; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Certificate of Analysis

  • Vincristine, also known as leurocristine, sometimes abbreviated "VCR", is a mitotic inhibitor.
  • Treatment with cyclophosphamide, hydroxydaunorubicin (doxorubicin, please see Cat. No. D-4000, Doxorubicin, Hydrochloride Salt and Cat. No. D-4099, Doxorubicin, Free Base), Oncovin® (vincristine), and prednisone (CHOP) has long been the standard therapy for non-Hodgkin's lymphoma. Improvements have been made to the efficacy of this regimen by increasing the dosing frequency and by adding rituximab immunotherapy to the regimen. Gisselbrecht, C. "Current approaches to the treatment of non-Hodgkin's lymphoma." Hematol. Rep. 3: e3 (2011).
  • ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) has been the standard of treatment for patients with advanced-stage Hodgkin lymphoma (HL). Kuruvilla, J. "Standard therapy of advanced Hodgkin lymphoma." Hematology Am. Soc. Hematol. Educ. Program 497-506 (2009).
  • Vincristine was metabolized in vitro more efficiently by CYP3A5 than by CYP3A4. In children with precursor B cell acute lymphoblastic leukemia, CYP3A5 expressers produced more primary metabolite (M1), had lower metabolic ratios of [vincristine]/[M1], and experienced less vincristine-induced peripheral neuropathy when compared to CYP3A5 non-expressers. Egbelakin, A., et al. "Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia." Pediatr. Blood Cancer 56: 361-367 (2011).
  • Sixty-three patients with advanced chronic lymphocytic leukemia were treated with vincristine, cyclophosphamide, BCNU, melphalan, and prednisone (M-2 protocol). Complete remission (CR) and partial response (PR) were achieved in 17% and 44%, respectively. The median survivals of patients achieving a CR, PR, or no response were 73+, 40, and 14 months, respectively. Kempin, S., et al. "Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone)." Blood 60: 1110-1121 (1982).
  • Exposure of platelets to vincristine resulted in disassembly of microtubules, loss of discoid shape, formation of tubulin crystals, a depressed response to aggregating agents, and reduced secretory activity. White, J.G. and Rao, G.H. "Effects of a microtubule stabilizing agent on the response of platelets to vincristine." Bloo 60: 474-483 (1982).
  • Vincristine is the active ingredient in the drug sold under the trade name Oncovin®. This drug is currently approved in at least one country for use to treat patients with cancers in various types of chemotherapy regimens. NOTE: THE VINCRISTINE, SULFATE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT ONCOVIN®, AND IS NOT FOR HUMAN USE.
  • Related CAS number: 57-22-7 for the free base.
  • We tested the purity of Tocris's vincristine product, their Cat. No. 1257, Batch 3A, and found HPLC purity of only 82% instead of the claimed 96%. Proton NMR also showed purity lower than claimed.
  • STRUCTURE ERRORS ON WIKIPEDIA AND FOUR VENDORS' WEBSITES: As of December 21, 2012, the vincristine structures shown on Wikipedia and at least four vendors' (Cayman, Santa Cruz, Selleck, and Sigma) web pages are incorrect in one or more ways. (We have not checked most other vendors' vincristine structures.) Also, the vincristine structure shown on Chemblink fails to specify the stereochemistry at two asymmetric carbon atoms. Finally, the Merck Index Vol. 14 entry for vincristine shows a dashed bond connecting a nitrogen atom and a symmetrically substituted carbon atom; this appears to be a bond that would not normally be shown as embodying stereochemical information, so our structure shows it as a plain single bond.
  • Vincristine is the active ingredient in drug products sold under numerous trade names, such as those listed near the top of this page as "Related Terms". These drug products have been approved in at least one country for use in patients with cancer. NOTE: THE VINCRISTINE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT ANY OF THE VINCRISTINE-CONTAINING DRUG PRODUCTS SOLD UNDER VARIOUS TRADE NAMES AND IS NOT FOR HUMAN USE.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.